By Staff
The C$473B Caisse de dépôt et placement du Quebec and Brookfield Asset Management’s private equity business have acquired a stake in Antylia Scientific for roughly $1.3B.
“We are investing with our long-standing partner Brookfield in Antylia, a business supplying critical products to professionals in the life and environmental sciences sectors,” said Martin Longchamps, the pension fund’s executive vice-president and head of private equity and private credit, in a press release. “Together, we see an opportunity to support its continued growth and reinforce its position as a market leader.”
Vernon Hills, Ill.-based Antylia is a manufacturer and distributor of consumables and testing equipment serving diagnostics, environmental, and life sciences labs. CDPQ’s investment in the organization was made both directly as a “significant minority investor in the transaction” and indirectly as a limited partner through one of Brookfield’s private equity funds, according to a company spokesperson.
CDPQ’s private equity portfolio had returned 17.2%, or C$13B, by December 31, according to its latest annual report. The five-year annualized return for the portfolio was 15.4% by the end of 2024, compared to 14.1% for its benchmark index. By the end of last year, CDPQ’s net assets in its equities portfolio reached C$219.4B, with private equity accounting for C$90.0B of that total.
As of December 31, 41% of the pension fund’s private equity exposure was located in the U.S., compared to 32% in Europe, 18% in Canada, 7% in Asia Pacific, and 2% in Latin America.
